Transgender Polling Archive
probability panel

Ipsos

Axios-Ipsos American Health Index, Wave 1 · Feb 17–21, 2023 · US national

Methodology

Pollster
Ipsos commercial
Sponsor
Axios
Commissioned by
Axios
Fielded
Feb 17–21, 2023
Population
adults
Sample size
1,213
Sample frame
probability panel
Panel
Ipsos KnowledgePanel
Mode
online - self-administered web survey of the probability-based KnowledgePanel; address-based sampling via the USPS Delivery Sequence File; tablet and internet provided to households without access
Margin of error
+/- 3.0 percentage points at the 95% confidence level for the entire sample of adults (design-effect adjusted)
Weighting
Weighted to adjust for gender by age, race/ethnicity, education, Census region, metropolitan status, household income, and party ID
Geography
US national
Base notes
The published topline reports wave-level totals only; no party or demographic crosstabs are printed in the topline PDF.

Sources

Verification note. Full 18-page Axios-Ipsos topline retrieved and text-extracted. I scanned all twelve published waves of the Axios-Ipsos American Health Index (Feb 2023 through Q2 2026); only Wave 1 and Wave 2 contain trans-related items, so the insurance-coverage item below is a single fielding rather than a tracker point despite appearing in a tracking instrument. No party breaks are published in the Axios-Ipsos toplines.

Figures below are transcribed from these documents. Where they disagree with the source, the source governs.

Questions asked (1)

Adult medical caresupport/opposein a trend series
health insurance coverage of transgender-related medical care

How much do you support or oppose the following?

How much do you support or oppose the following? Health insurance companies covering transgender-related medical care

Support 47%52% Oppose

Wording notes: no age qualifier - 'transgender-related medical care' covers adults and minors alike, so respondents may be answering about different populations | no 'don't know' offered; only 'Skipped' (2%) | asked inside a health-insurance battery alongside obesity drugs, insulin caps and COVID quarantine, which frames it as a coverage-economics question rather than a culture-war one

neutral — Neutrally worded with a balanced four-point scale, and the battery placement is genuinely useful - asking about trans care next to obesity drugs and insulin puts it in an ordinary insurance-coverage frame rather than a political one. The one real limitation is the missing age qualifier. The comparison within the battery is striking: 78% support insurers covering obesity drugs versus 47% for transgender-related care, with 33% strongly opposed.

Every figure on this page is transcribed from the source linked above. How to read this data →